Laboratory diagnostics use blood measurements of amyloid beta and tau protein levels, which help to distinguish dementia of other etiologies from Alzheimer’s disease, but the required equipment significantly limits its use in clinical practice. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.